|

Multiple Sclerosis Clinical Trials in New York, NY

40 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPhase 3<1 mi
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)Phase 2<1 mi
Task Specific Training for Advanced Multiple SclerosisN/A<1 mi
Noninvasive Vagal Nerve StimulationN/A<1 mi
Vancomycin Study in Multiple Sclerosis (MS)Phase 1<1 mi
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersPhase 1<1 mi
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsPhase 2<1 mi
A Palliative Care Model Impact on Knowledge and AttitudesN/A<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 4<1 mi
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSPhase 2<1 mi
NYSCF Scientific Discovery Biobank—<1 mi
A Study of the MIND Diet for Persons With Multiple SclerosisN/A<1 mi
Effect of Cooling on Balance Performance in Multiple Sclerosis—<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Phase 3<1 mi
A Study of AZD0120 in Autoimmune DiseasesPhase 1<1 mi
Genes and Environment in Multiple Sclerosis—<1 mi
An Open-label Study of AZD0120 in Adults With Multiple SclerosisPhase 1<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3<1 mi
Eccentric Exercise and Fatigue in Multiple Sclerosis—<1 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Phase 1<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2<1 mi
Effectiveness of Task Specific Home Exercise ProgramN/A5 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPhase 312 mi
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis—12 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/212 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisPhase 313 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 313 mi
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI—14 mi
An Examination of Cognitive Fatigue Using Functional Neuroimaging—14 mi
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI—14 mi
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MSN/A14 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Phase 316 mi
Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the CommunityN/A20 mi
Meeting an Unmet Need in Multiple SclerosisN/A20 mi
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple SclerosisN/A20 mi
Neurologic Stem Cell Treatment StudyN/A45 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.